ClinicalTrials.gg
RecruitingNCT05907655Updated Nov 6, 2026

Study of the Glymphatic System in Migraine

An observational study in Migraine, sponsored by IRCCS San Raffaele. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by IRCCS San Raffaele · Observational

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 6 months later.
Updated Nov 6, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 115 studies in Migraine Disorders with a site in Italy — 37 open to participants now, 47 under way, 13 of them phase 3. Migraine Disorders · Italy.

Planned enrollment
34th of 42
50 · median 108
Started
2023
with 18 others
Observational
42 of 115
26 open now
Primary completion
2027-03
later than 29 of 46 live
Registered
70th of 115
by date

Among the 115 studies in Migraine Disorders with a site in Italy, this one is the 34th largest by planned enrollment of the 42 observational ones that give a count, is one of 19 that started in 2023, is one of 42 observational ones, reaches primary completion later than 29 of the 46 other live ones, and was the 70th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

37 of the 115 studies in Migraine Disorders with a site in Italy are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in Migraine Disorders with a site in Italy, or all of them as a file.
02

Study summary

This study aimed to investigate the role of the glymphatic system in the initiation of migraine attacks, using non-invasive magnetic resonance imaging techniques and a validated model of migraine induction by nitroglycerin administration. Secondarily, the relationship between the function of the glymphatic system during nitroglycerin-induced migraine attacks and sleep architecture and plasma levels of migraine-involved neuropeptides will be investigated.

03

Conditions studied

  • Migraine

Browse trials for

Keywords

  • migraine
  • MRI
  • glymphatic system
  • sleep
  • neuropeptides
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with a diagnosis of episodic migraine without aura, by the standard ICHD diagnostic criteria, will be prospectively recruited. Patients will be allowed to take only one migraine preventive treatment at a stable dose during the study. Healthy controls suffering from any headaches with the exception of infrequent tension-type headache will be excluded from the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For patients:

  • Diagnosis of migraine, by the ICHD-3 criteria;

For both patients and healthy controls:

  • Age between 18 and 60 years;
  • Willing and able to comply with scheduled visits.

Exclusion criteria

Exclusion criteria

For patients:

  • Overuse of acute medications for headache;
  • Continuous or daily headache;
  • Other primary headache disorders, with the exception of infrequent tension-type headache.

For healthy controls:

  • Any subject with frequent tension type headache, migraine, cluster headache, other pain syndromes or neurological conditions.

For both patients and healthy controls:

  • Allergy to nitroglycerin;
  • Major psychiatric disorders such as bipolar affective disorder and schizophrenia;
  • Cardiovascular diseases that the use of nitroglycerin;
  • Intracranial hypertension;
  • Cerebral haemorrhage;
  • Cerebral trauma;
  • Pulmonary toxic oedema;
  • Closed angle glaucoma;
  • Anaemia;
  • Pregnancy and breastfeeding;
  • Aortic stenosis or significant hypotension (SBP\<90mmHg or \<100mmHg and symptomatic) precluding nitroglycerin administration;
  • Use of sildenafil;
  • Any person unable to lie still within the environment of the MRI scanner for the required period to perform the study;
  • Any person where MRI scanning is contraindicated (metal implants, pacemaker, claustrophobia, etc.);
  • Use of illicit drugs;
  • MRI head showing any brain pathology, such as space-occupying lesions;
  • Any person unable to understand and follow the instructions of the investigators.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adult patients with migraine

    Diagnosis of migraine, by the ICHD-3 criteria. Age between 18 and 60 years. Female and males. Right-handed

    Drug: Nitroglycerin 0.3 MG · Diagnostic Test: MRI · Diagnostic Test: Blood sampling · Device: Sleep profiler

  • Healthy controls

    Age between 18 and 60 years. Female and males. Right-handed

    Drug: Nitroglycerin 0.3 MG · Diagnostic Test: MRI · Diagnostic Test: Blood sampling · Device: Sleep profiler

Interventions

  • DrugNitroglycerinStudies of NitroglycerinNitroglycerin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Sublingual nitroglycerin will be used to provoke spontaneous-like migraine attacks in migraine patients. A dose of 0.9 mg of sublingual nitroglycerin will be used. The same dose will be administrated to controls.

  • Diagnostic testMRI

    The following brain MRI sequences will be acquired before and after nitroglycerin administration: fluid attenuated inversion recovery (FLAIR), 3D T1-weighted inversion recovery prepared gradient echo, diffusion weighted sequence and 3D susceptibility weighted images.

  • Diagnostic testBlood sampling

    Plasma levels of neuropeptides involed in migraine will be measured using commercially available enzyme-linked immune-sorbent assay (ELISA) kits. All ELISA will be performed by the same experienced technician who will be blinded for the clinical diagnosis.

  • DeviceSleep profiler

    Sleep architecture will be investigated using the Sleep Profiler. Sleep Profiler is medical device with CE mark which is produced by Advanced Brain Monitoring and distributed throughout Italy exclusively by Medigas. Sleep staging will be automatically performed for 30-second epochs throughout a dedicated software and a standardized and validated procedure. Frontopolar EEG signal waveforms will be visually inspected to confirm the accuracy of the auto-staging.

06

What researchers measure

Primary outcomes

  1. Change from baseline glymphatic function after nitroglycerin administration

    The DTI-ALPS index will be quantified before and after nitroglycerin administration as an indirect measure of the glymphatic function

    Time frame: Up to 8 hours

Secondary outcomes

  1. Change from baseline plasma levels of neuropeptides after nitroglycerin administration

    ELISA kits will be used to measure the plasma level of neuropeptides involved in migraine pathophysiology before and after nitroglycerin administration

    Time frame: Up to 8 hours

  2. Change from baseline sleep architecture after nitroglycerin administration

    Sleep Architecture will be studied through the Sleep Profiler before and after nitroglycerin administration

    Time frame: Up to 8 hours

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Mar 2027, 47 months after the start.

Of 132 non-industry observational studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 72. This study's planned 47 months is above that.

Counting every sponsor, half of 160 studies reached it within 27 months; a quarter within 12 and three quarters within 63.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Jun 2025 → Mar 2027 and completion Apr 2026 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2023
First posted
Jun 18, 2023
StartActual
Apr 30, 2023
Primary completionEst.
Mar 30, 2027was Jun 2025
CompletionEst.
Apr 4, 2027was Apr 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • IRCCS San Raffaele Hospital · Milan, Italy
Show 1 removed
  • IRCCS San Raffaele Hospital · Milan, Italy
Nov 6, 2026
Primary completion
Jun 30, 2025→Mar 30, 2027
Nov 6, 2026
Study completion
Apr 30, 2026→Apr 4, 2027
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    1 site added, 1 site removed
    Show site
    • IRCCS San Raffaele Hospital · Milan, Italy
    Show 1 removed
    • IRCCS San Raffaele Hospital · Milan, Italy
    Primary completion Jun 30, 2025→Mar 30, 2027
    Study completion Apr 30, 2026→Apr 4, 2027
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05907655
Lead sponsor
IRCCS San Raffaele
Responsible party
Roberta Messina (Principal Investigator, IRCCS San Raffaele) — Principal investigator
First posted
Jun 18, 2023
Start date
Apr 30, 2023
Primary completion
Mar 30, 2027 (estimated)
Completion
Apr 4, 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Roberta Messina, MD, PhD
Contact
messina.roberta@hsr.it
00390226433944
Roberta Messina, MD, PhD
principal investigator · IRCCS San Raffaele Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion